The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial
Abstract
Mutations of members of the ras family are among the most common oncogene mutations found in multiple myeloma (MM). We have examined the mutational status of the N- and K-ras genes at codons 12, 13, and 61 in 160 newly diagnosed MM patients enrolled on the Eastern Cooperative Oncology Group (ECOG) phase III clinical trial E9486. The total incidence of ras mutations was found to be 39% of the samples analyzed. Five patients showed evidence of more than one mutation. We obtained 22 marrow samples from patients at the time of disease progression or relapse, for whom a ras mutation was identified at diagnosis. In all cases, the ras mutation of the disease progression sample was identical to that found at diagnosis. In contrast, three of 25 patients who did not show any ras mutation at diagnosis acquired a ras mutation at the time of disease progression. No significant association was observed between any ras mutation and stage of disease, beta 2-microglobulin levels, labelling index, or protein type. The mean tumor burden and median survival for patients with mutations of N-ras was indistinguishable from patients with no ras mutations. However, patients with K-ras mutations had a significantly higher mean bone marrow tumor burden at diagnosis than patients with no ras mutations (57% v 36%, P ‼ .02); and the median survival of patients with a K-ras mutation was significantly shorter (2.0 v 3.7 years, P ‼ .02). To determine if the status of ras mutations could affect treatment response, we examined patient survival on the three treatment arms of E9486. Although the presence of a ras mutation in the multidrug treatment, VBMCP alone, showed a marginal significance, neither the VBMCP, nor the addition of interferon-alpha showed statistically significant survival differences between mutant and wildtype ras status. Interestingly, there appeared to be a statistically significant difference in survival of patients treated with VBMCP and alternating high doses of cyclophosphamide + prednisone. Patients with ras mutations had a median survival of 2.1 years; patients with wild-type ras had a median survival of 4.0 years (P ‼ .01).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with MM harboring oncogenic KRAS mutations tend to have worse clinical outcomes than those with NRAS mutations or wild-type RAS [95].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [95]
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Orita, M., Suzuki, Y., Sekiya, T., & Hayashi, K. (1989) · Genomics · doi:10.1016/0888-7543(89)90129-8 · Cited by 3,419
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Mashiyama, S., Kayama, T., Katakura, R., Yoshimoto, T., Murakami, Y., Sekiya, T., & Hayashi, K. (1991) · Springer eBooks · doi:10.1007/978-4-431-68150-2_41 · Cited by 538
Quelle, F. W., Sato, N., Witthuhn, B. A., Inhorn, R. C., Eder, M., Miyajima, A., Griffin, J. D., & Ihle, J. N. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4335 · Cited by 471
Sato, N., Sakamaki, K., Terada, N., Arai, K., & Miyajima, A. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06102.x · Cited by 355
“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up
Kyle, R. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60015-9 · Cited by 344
Self-citationA dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides
Vries, M. V., Bogaard, M. E., van den Elst, H., van Boom, J. H., van der Eb, A. J., & Bos, J. L. (1986) · Gene · doi:10.1016/0378-1119(86)90335-5 · Cited by 331
Satoh, T., Nakafuku, M., Miyajima, A., & Kaziro, Y. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3314 · Cited by 329
Cited by
Sorted by citations
Items 201–215 of 215
Advances in the Biology and Treatment of Multiple Myeloma
Berenson, J. R., & Vescio, R. A. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-308-8_9
Signaling pathways involved in B cell differentiation and disease : the role of Ral, Btk and Met
de Gorter, D. J. J. (2008) · UvA-DARE (University of Amsterdam)
Alterações moleculares no Mieloma Múltiplo
Braggio, E., & Renault, I. Z. (2007) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842007000100004
Xu, F., Sharma, S., Gardner, A. M., Raitano, A. B., & Sawyers, C. L. (2011)
Studies of Interactions Between Myeloma Cells and Osteoblasts: In Vitro
Karadağ, A. (2019) · OpenGrey (Institut de l'Information Scientifique et Technique)
Polymer Microsystems for the Enrichment of Circulating Tumor Cells and their Clinical Demonstration
Kamande, J. W. (2013) · Louisiana State University · doi:10.31390/gradschool_dissertations.2652
Multiple Myeloma and Other Plasma Cell Neoplasms
Ng, A. K., Anderson, K. C., & Mahindra, A. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00076-6
Review The role of the bone marrow microenvironment in multiple myeloma
Vanderkerken, K. (2005)
Huang, Y.-H. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-hc63-hp64
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt011
Schuster, S. R., Braggio, E., & Fonseca, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4660-6_1
Li, N., Lin, P., Zuo, Z., You, M. J., Wen, S., Orlowski, R. Z., Manasanch, E. E., Li, S., Xu, J., Garces, S. A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1879409/v1
Subbiah, V., Puzanov, I. J., Blay, J., Chau, I., Lockhart, A. C., Raje, N. S., Wolf, J., Baselga, J. M., Meric‐Bernstam, F., Roszik, J., et al. (2023) · doi:10.1158/2159-8290.22535054
New Therapeutic Approaches to Myeloma
Landowski, T. H., Dalton, W. S., & Salmon, S. E. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-817-5_16
The Mammalian Target of Rapamycin and Multiple Myeloma
Frost, P., & Lichtenstein, A. K. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_21
Metadata
- Authors
- Liu, P., Leong, T., Quam, L., Billadeau, D., Kay, N., Greipp, P., Kyle, R., Oken, M., & Van Ness, B.
- Affiliations
- University of Minnesota (US)
- University of Minnesota, Minneapolis, USA.
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1996-10-01
- Volume
- 88
- Issue
- 7
- Pages
- 2699-2706
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2294883787
- Cited by
- 215
- References
- 37
- Citations by year
- 2025: 1 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 4 · 2017: 3 · 2016: 8 · 2015: 7 · 2014: 6 · 2013: 7 · 2012: 15
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA32218, CA 15947, CA19853)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- multiple myeloma, NRAS mutation, KRAS mutation, oncogenic Ras, codon 12 and 13 mutations, disease progression, survival, interferon-alpha, prognostic factors
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow, Carmustine, Clone Cells, Codon, Combined Modality Therapy, Cyclophosphamide, DNA Mutational Analysis, DNA, Neoplasm, Female, Humans, Immunologic Factors, Male, Melphalan, Middle Aged, Multiple Myeloma, Prednisone, Prognosis, Genes, ras, Polymorphism, Restriction Fragment Length, Vincristine, Life Tables, Survival Analysis, Interferon-alpha, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
